These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25519702)

  • 1. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
    Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
    Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
    Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
    Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
    Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
    Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
    Nagaraj NS; Washington MK; Merchant NB
    Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
    Pan Y; Xu Y; Feng S; Luo S; Zheng R; Yang J; Wang L; Zhong L; Yang HY; Wang BL; Yu Y; Liu J; Cao Z; Wang X; Ji P; Wang Z; Chen X; Zhang S; Wei YQ; Yang SY
    Mol Cancer Ther; 2012 Apr; 11(4):952-62. PubMed ID: 22319204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
    Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
    Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
    Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
    Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway.
    Yang L; Lin S; Kang Y; Xiang Y; Xu L; Li J; Dai X; Liang G; Huang X; Zhao C
    J Exp Clin Cancer Res; 2019 Jan; 38(1):31. PubMed ID: 30674340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
    Pathania D; Kuang Y; Sechi M; Neamati N
    Br J Pharmacol; 2015 Jan; 172(1):50-63. PubMed ID: 25047070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin.
    Peng T; Wu JR; Tong LJ; Li MY; Chen F; Leng YX; Qu R; Han K; Su Y; Chen Y; Duan WH; Xie H; Ding J
    Acta Pharmacol Sin; 2014 Jul; 35(7):916-28. PubMed ID: 24858311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
    Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
    Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.
    Lang SA; Schachtschneider P; Moser C; Mori A; Hackl C; Gaumann A; Batt D; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2008 Nov; 7(11):3509-18. PubMed ID: 19001434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
    Guo XB; Chen XJ; Tong LJ; Peng X; Huang M; Liu HC; Liu H; Ding J
    Acta Pharmacol Sin; 2015 Oct; 36(10):1266-76. PubMed ID: 26027659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
    Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
    Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB
    Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
    Lu YY; Jing DD; Xu M; Wu K; Wang XP
    World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
    Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
    BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.